FDA

#Corcept Therapeutics #FDA #Hypertension

Regulator requests “additional evidence” for hypertension drug 

The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Corcept Therapeutics regarding the New Drug Application (NDA) for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.  While the FDA acknowledged that Corcept’s pivotal GRACE trial met its primary endpoint and that… Read More

#News #Regulatory

Woman with motion sickness
#FDA #Gastroenterology #Vanda Pharmaceuticals

FDA approval a milestone in the prevention of motion sickness

The US Food and Drug Administration (FDA) has approved Vanda Pharmaceuticals’ Nereus (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of vomiting induced by motion.   The approval marks the first new pharmacologic treatment in motion sickness in over four decades, representing a significant advancement in the understanding and… Read More

#News #Regulatory

FDA
#FDA #GLP-1 #Novo Nordisk #Obesity #Weight loss

FDA approves first oral GLP-1 for weight management

The US Food and Drug Administration (FDA) has approved the Wegovy pill (once-daily oral semaglutide 25mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events.  The Wegovy pill is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy… Read More

#News #Regulatory #Trending News

Demyelination of neuron
#FDA #Priority Review #SynaptixBio

Rare disease drug development scheme welcomed by biotech sector 

The renewal of the US priority review voucher (PRV) is vital for the biotech sector, SynaptixBio CEO Dan Williams has said.  The US Food and Drug Administration (FDA)’s PRV scheme, designed to incentivise rare disease drug development, was reauthorised by the US House of Representatives on December 1.   Williams, whose company is… Read More

#News #Regulatory

#AI #Cell and gene therapy #Charles River #Drug discovery #European Commission #European Union #FDA #Immune cells #Korea #Obesity #Personalised medicine #Rare disease #Regulatory

DDW Highlights: 23 December 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a research team found that a hidden molecular switch fuels obesity. Elsewhere, AI-generated… Read More

#Podcasts

#AI #Cell and gene therapy #Charles River #Drug discovery #European Commission #European Union #FDA #Immune cells #Korea #Obesity #Personalised medicine #Rare disease #Regulatory

This week in Drug Discovery (15 – 19 December) 

News round-up for 15 – 19 December by Bruno Quinney, Content Team at DDW.  This week in DDW, a research team found that a hidden molecular switch fuels obesity. Elsewhere, AI-generated antibodies have been tolerated by human immune cells.  The top stories:    Scientists discover hidden molecular switch that… Read More

#News

#Advanced Therapies #Cell and gene therapy #FDA #Gene therapy #Rare disease

FDA approves first gene therapy for Wiskott-Aldrich syndrome

The US Food and Drug Administration (FDA) has approved Waskyra (etuvetidigene autotemcel), the first cell-based gene therapy for the treatment of Wiskott-Aldrich syndrome (WAS). Waskyra is indicated for paediatric patients six months and older and adults with WAS who have a mutation in the WAS gene and for whom haematopoietic… Read More

#Editor's Choice #News #Regulatory

CAR-T for large B-cell lymphoma
#Advanced Therapies #Bristol Myers Squibb #FDA #Haematology #Lymphoma #Oncology

FDA approves first CAR-T therapy for marginal zone lymphoma

The US Food and Drug Administration (FDA) has approved a new indication for Breyanzi (lisocabtagene maraleucel) as the first chimeric antigen receptor (CAR)-T therapy in the US for treatment of adults with marginal zone lymphoma (MZL) who have failed treatment with or relapsed after two or more prior lines of… Read More

#News #Regulatory

Red blood cells
#blood #FDA #Grifols

FDA approves label expansion to treat blood-clotting disorder 

The US Food and Drug Administration (FDA) has approved an expanded indication for Thrombate III, the Grifols-developed drug treating a rare blood-clotting disorder.  Thrombate III is used to prevent hereditary antithrombin deficiency (hATd), becoming the only antithrombin concentrate (ATc) to be approved in both adult and paediatric patients.  The decision by the FDA follows the… Read More

#News #Regulatory

FDA headquarters
#Cell and gene therapy #FDA #Personalised medicine #Regulatory

FDA introduces new pathway for personalised medicines

The US Food and Drug Administration (FDA) has laid out the process and requirements of its novel plausible mechanism pathway for personalised medicine in a New England Journal of Medicine (NEJM) editorial by Commissioner Martin Makary and Deputy Vinay Prasad.  The editorial acknowledges that personalised therapies “challenge traditional models of… Read More

#News #Regulatory #Trending News

Diffuse large B-cell lymphoma
#CAR T-cell therapy #FDA #Lymphoma

FDA grants RMAT designation to T-cell lymphoma candidate 

The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to MB-105, a CAR-T cell therapy developed by biotechnology company March Biosciences.  The designation was granted based on data from March Bio’s ongoing multi-centre Phase II clinical trial. Preliminary findings from the safety run-in cohort… Read More

#News #Regulatory

Mitochondria
#FDA #Mitochondria

FDA approval of first TK2d drug offers ‘hope for the future’ 

The US Food and Drug Administration (FDA) has approved the first treatment for thymidine kinase 2 deficiency (TK2d), paving the way for landmark treatment options for the mitochondrial disease.  Doxecitine and doxribtimine, approved by the FDA, are oral solutions developed by biopharmaceutical company UCB. The powder, also known as Kygevvi, has been approved… Read More

#News

Cancer research
#Clinical trial #FDA #nda

Relief Therapeutics announces positive results for PKU treatment 

Biopharmaceutical company Relief Therapeutics has announced positive results from its bioequivalence study of RLF-OD032 for the treatment of phenylketonuria (PKU).  The study achieved its primary pharmacokinetic endpoints, demonstrating that RLF-OD032 is bioequivalent to KUVAN Powder, the reference listed drug, as defined by the US Food and Drug Administration… Read More

#News

Woman suffering from hot flushes
#Bayer #FDA #Menopause #Women's health

Bayer’s new approach to hot flashes receives FDA approval

The US Food and Drug Administration (FDA) has approved Lynkuet (elinzanetant) 60mg capsules, the first and only dual neurokinin (NK) targeted therapy,1 neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist, for the treatment of moderate to severe hot flashes due to menopause.  Inhibition of Substance P and Neurokinin B… Read More

#News #Regulatory

Multiple myeloma
#Clinical trial #FDA #Myeloma

FDA grants Fast Track Designation to myeloma treatment HDP-101

The US Food and Drug Administration has granted Fast Track Designation to myeloma candidate HDP-101 from Heidelberg Pharma.  The designation was supported by nonclinical data as well as clinical data from the ongoing Phase I/IIa study with HDP-101, evaluating the safety and antitumour activity of the candidate in patients with… Read More

#News #Regulatory

#FDA #US government

Trump praises infertility product awarded FDA ‘voucher’

US President Donald Trump has welcomed the US Food and Drug Administration (FDA) awarding a ‘voucher’ to infertility product Pergoveris as part of an unprecedented new scheme.  Pergoveris was one of nine recipients of FDA vouchers handed out under the new Commissioner’s National Priority Voucher (CNPV) pilot… Read More

#News